Article Details
Retrieved on: 2018-02-06 23:33:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>New Enterprise Associates</b> led the Series A funding round, which Borland says will support work bringing two compounds, one for migraines and another for Parkinson's disease, into clinical trials. Borland already has experience in migraine drug development. He was a senior neurology executive at ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here